Krystal Biotech Q2 EPS Forecast Decreased by HC Wainwright

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Equities research analysts at HC Wainwright decreased their Q2 2025 EPS estimates for shares of Krystal Biotech in a research note issued on Monday, June 30th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of $1.26 for the quarter, down from their prior forecast of $1.71. HC Wainwright currently has a "Buy" rating and a $240.00 price target on the stock. The consensus estimate for Krystal Biotech's current full-year earnings is $6.14 per share. HC Wainwright also issued estimates for Krystal Biotech's Q3 2025 earnings at $1.58 EPS, Q4 2025 earnings at $2.12 EPS and FY2025 earnings at $5.71 EPS.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). The business had revenue of $88.18 million for the quarter, compared to the consensus estimate of $98.66 million. Krystal Biotech had a net margin of 37.17% and a return on equity of 14.64%.

Several other research analysts have also recently issued reports on the company. Jefferies Financial Group initiated coverage on Krystal Biotech in a research note on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price target for the company. Guggenheim lowered their target price on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Chardan Capital reaffirmed a "buy" rating and issued a $219.00 price target on shares of Krystal Biotech in a research note on Wednesday, May 7th. Finally, Citigroup decreased their price objective on shares of Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating for the company in a report on Friday, May 16th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $211.13.

Krystal Biotech Trading Up 1.7%

KRYS traded up $2.34 during trading hours on Wednesday, hitting $141.35. The company's stock had a trading volume of 209,978 shares, compared to its average volume of 287,117. The company has a 50-day simple moving average of $139.58 and a 200 day simple moving average of $157.23. The firm has a market capitalization of $4.09 billion, a PE ratio of 33.98 and a beta of 0.67. Krystal Biotech has a fifty-two week low of $122.80 and a fifty-two week high of $219.34.

Hedge Funds Weigh In On Krystal Biotech

Several large investors have recently made changes to their positions in KRYS. Brooklyn Investment Group raised its holdings in shares of Krystal Biotech by 291.7% in the 1st quarter. Brooklyn Investment Group now owns 141 shares of the company's stock worth $25,000 after purchasing an additional 105 shares in the last quarter. Twin Tree Management LP acquired a new position in Krystal Biotech in the first quarter worth approximately $29,000. Fifth Third Bancorp increased its holdings in shares of Krystal Biotech by 159.1% in the first quarter. Fifth Third Bancorp now owns 171 shares of the company's stock valued at $31,000 after buying an additional 105 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in shares of Krystal Biotech by 128.3% during the 1st quarter. Smartleaf Asset Management LLC now owns 315 shares of the company's stock valued at $58,000 after acquiring an additional 177 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of Krystal Biotech during the 1st quarter valued at $74,000. Institutional investors own 86.29% of the company's stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).